Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac Cancels mRNA Contracts For COVID-19 Jab

09/15/2021 | 01:42am EDT


ę MT Newswires 2021
All news about CUREVAC N.V.
10/15CureVac Shares Down 12%
DJ
10/13CUREVAC N : EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by Cur..
AQ
10/12CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
MT
10/12Health Care Stocks Extending Retreat Ahead of Tuesday Close
MT
10/12Equities Choppy Midday as Clarida Says Fed Would Respond to Rise in Inflation Expectati..
MT
10/12MIDDAY REPORT : US Stocks Choppy as Clarida Says Fed Would Respond to Rise in Inflation Ex..
MT
10/12Health Care Stocks Falling Despite Moderate Rise Among Biotech Companies
MT
10/12CUREVAC N : Drops COVID-19 Vaccine to Focus on Second-Generation Shot with GlaxoSmithKline
MT
10/12Wall Street Set for Cautiously Higher Open, Earnings Season Eyed
MT
10/12Health Care Stocks Edge Higher Premarket Tuesday
MT
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2021 147 M 170 M 170 M
Net income 2021 -325 M -377 M -377 M
Net cash 2021 1 446 M 1 676 M 1 676 M
P/E ratio 2021 -17,4x
Yield 2021 -
Capitalization 6 413 M 7 440 M 7 433 M
EV / Sales 2021 33,9x
EV / Sales 2022 0,22x
Nbr of Employees 505
Free-Float 48,7%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 34,33 €
Average target price 65,23 €
Spread / Average Target 90,0%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-50.88%7 440
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414